1. 1. European Directorate for Quality in Medicines and Healthcare (EDQM). European Pharmacopoeia 10.0, Monograph 2.9.18. Preparations for Inhalation: Aerodynamic Assessment of Fine Particles. EDQM: Strasburg, France; 2021.
2. 2. United States Pharmacopeial Convention (USP). United States Pharmacopeia General Chapter <601> Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders, official as of May 1, 2021. USP: Rockville, MD, USA; 2021.
3. 3. Tougas TP, Mitchell JP, Lypustina SA. (eds.) Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products. Springer: New York, NY, USA; 2013.
4. Next Generation Pharmaceutical Impactor (A New Impactor for Pharmaceutical Inhaler Testing). Part I: Design
5. 5. Versteeg HK, Roberts DL, Cooper A, et al. Understanding the Transient Flow Behavior of Abbreviated Impactors for Testing of Dry-Powder Inhalers. In: Drug Delivery to the Lung 33, The Aerosol Society, Edinburgh, Scotland, December 7–9, 2022; pp. 237–240.